Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors

Tadaaki Nishikawa, Koji Matsumoto, Kenji Tamura, Hiroyuki Yoshida, Yuichi Imai, Aki Miyasaka, Takuma Onoe, Satoshi Yamaguchi, Chikako Shimizu, Kan Yonemori, Tatsunori Shimoi, Mayu Yunokawa, Hao Xiong, Silpa Nuthalapati, Hideyuki Hashiba, Tsukasa Kiriyama, Terri Leahy, Philip Komarnitsky, Keiichi Fujiwara, Tadaaki Nishikawa, Koji Matsumoto, Kenji Tamura, Hiroyuki Yoshida, Yuichi Imai, Aki Miyasaka, Takuma Onoe, Satoshi Yamaguchi, Chikako Shimizu, Kan Yonemori, Tatsunori Shimoi, Mayu Yunokawa, Hao Xiong, Silpa Nuthalapati, Hideyuki Hashiba, Tsukasa Kiriyama, Terri Leahy, Philip Komarnitsky, Keiichi Fujiwara

Abstract

Veliparib (ABT-888) is a potent, orally bioavailable poly(ADP-ribose) polymerase-1 and -2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single-agent veliparib in Japanese patients with advanced solid tumors. Eligible patients were assigned to treatment with veliparib at 200 or 400 mg dose; veliparib was self-administered orally twice daily on days 1-28 of 28-day cycles. Dose escalation, following a 3 + 3 design, defined dose-limiting toxicities, the maximum tolerated dose, and the recommended phase 2 dose. Sixteen patients were enrolled (median age, 59 years). Fourteen patients had high-grade serous ovarian cancer, one had primary peritoneal cancer, and one had BRCA-mutated breast cancer. The most frequent treatment-emergent adverse events were nausea and vomiting (93.8% each), decreased appetite (62.5%), abdominal pain, diarrhea, and malaise (31.3% each). A grade ≥3 toxicity was observed in 50% of patients; one patient each in the 200 mg (n = 4) and 400 mg (n = 12) cohorts experienced serious adverse events. Dose-limiting toxicities were observed for one patient at the 400 mg dose. No toxicities leading to death were reported. The recommended phase 2 dose was defined as 400 mg twice daily. The veliparib pharmacokinetic profile was consistent with that reported for the Western population. Two patients, both with ovarian cancer, had a RECIST partial response. Veliparib monotherapy showed manageable tolerability and safety profiles and a predictable pharmacokinetic profile at a 400 mg twice-daily dose, and supports the inclusion of Japanese patients in the multinational phase 3 study (NCT02470585).

Keywords: High-grade serous ovarian cancer; Japanese; phase 1; poly(ADP-ribose) polymerase; veliparib.

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Figures

Figure 1
Figure 1
(a) Mean (+SD) plasma concentration‐time profile of veliparib on cycle 1 day 1 following oral administration of 200 and 400 mg veliparib. (b) Comparison of dose‐normalized PK parameters of veliparib across studies. AUC inf, area under the plasma concentration‐time curve from time 0 to infinity; BID, twice‐daily; Cmax, maximum plasma concentration; h, hours; PK, pharmacokinetic.
Figure 2
Figure 2
Computed tomography images showing partial response in a single patient to veliparib 200 mg BID. BID, twice‐daily; C1D1, day 1 of cycle 1; CA‐125, cancer antigen 125; CT, computed tomography; PR, partial response; TL, target lesion.
Figure 3
Figure 3
(a) Best percentage change from baseline in the sum of tumor sizes of target lesions (treated population, in patients with measurable disease at baseline). (b) Percentage change from baseline in CA‐125 (treated population§). CA‐125, cancer antigen 125. †Patients with BRCA mutated tumor. ‡Platinum resistant patients – defined as patients who progressed on or within 6 months of completion of the last platinum‐based regimen. §One patient with breast cancer was not included in the CA‐125 response analysis.

References

    1. Wang ZC, Birkbak NJ, Culhane AC et al Profiles of genomic instability in high‐grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012; 18: 5806–15.
    1. Coleman MP, Forman D, Bryant H et al Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population‐based cancer registry data. Lancet 2011; 377: 127–38.
    1. National Cancer Institute . Surveillance, epidemiology, and end results program. Cancer stat facts: Ovarian cancer. [Cited 29 March 2017.] Available from URL: .
    1. International Agency for Research on Cancer . World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. [Cited 29 March 2017.] Available from URL: .
    1. Foundation for Promotion of Cancer Research . Cancer statistics in Japan – 2015. 2015. [Cited 29 March 2017.] Available from URL: .
    1. Haruta S, Furukawa N, Yoshizawa Y et al Molecular genetics and epidemiology of epithelial ovarian cancer (review). Oncol Rep 2011; 26: 1347–56.
    1. Pal T, Permuth‐Wey J, Betts JA et al BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807–16.
    1. Antoniou A, Pharoah PD, Narod S et al Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–30.
    1. Chen S, Parmigiani G. Meta‐analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329–33.
    1. Bowtell DD. The genesis and evolution of high‐grade serous ovarian cancer. Nat Rev Cancer 2010; 10: 803–8.
    1. Bowtell DD, Böhm S, Ahmed AA et al Rethinking ovarian cancer II: reducing mortality from high‐grade serous ovarian cancer. Nat Rev Cancer 2015; 15: 668–79.
    1. Matsumoto K, Onda T, Yaegashi N. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Jpn J Clin Oncol 2015; 45: 408–10.
    1. Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group . BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol 2011; 22(Suppl 6): vi31–4.
    1. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays 2004; 26: 882–93.
    1. Kaufman B, Shapira‐Frommer R, Schmutzler RK et al Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–50.
    1. Ledermann J, Harter P, Gourley C et al Olaparib maintenance therapy in platinum‐sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382–92.
    1. Ledermann J, Harter P, Gourley C et al Olaparib maintenance therapy in patients with platinum‐sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–61.
    1. Farmer H, McCabe N, Lord CJ et al Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–21.
    1. Bryant HE, Schultz N, Thomas HD et al Specific killing of BRCA2‐deficient tumours with inhibitors of poly(ADP‐ribose) polymerase. Nature 2005; 434: 913–7.
    1. European Medicines Agency . Summary of opinion: Lynparza (olaparib). 2014. [Cited 11 April 2017.] Available from URL: .
    1. US Food and Drug Administration . 2014. [Cited 11 April 2017.] Available from URL: .
    1. US Food and Drug Administration . 2016. [Cited 11 April 2017.] Available from URL: .
    1. US Food and Drug Administration . 2017. [Cited 11 April 2017.] Available from URL: .
    1. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015; 5: 1137–54.
    1. Donawho CK, Luo Y, Luo Y et al ABT‐888, an orally active poly(ADP‐ribose) polymerase inhibitor that potentiates DNA‐damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728–37.
    1. Puhalla S, Beumer JH, Pahuja S et al Final results of a phase 1 study of single‐agent veliparib (V) in patients (pts) with either BRCA1/2‐mutated cancer (BRCA+), platinum‐refractory ovarian, or basal‐like breast cancer (BRCA‐wt). J Clin Oncol 2014; 32(Suppl): abstract 2570.
    1. Coleman RL, Sill MW, Bell‐McGuinn K et al A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 137: 386–91.
    1. Steffensen KD, Adimi P, Jakobsen AK. Veliparib monotherapy to patients with BRCA germline mutation and platinum‐resistant or partially platinum‐sensitive relapse of epithelial ovarian cancer: a phase I/II study. J Clin Oncol 2016; 34(Suppl): abstract 5532.
    1. US Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. 2010. [Cited 29 March 2017.] Available from URL: .
    1. Eisenhauer EA, Therasse P, Bogaerts J et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47.
    1. Rustin GJ, Quinn M, Thigpen T et al Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487–8.
    1. Mostafa NM, Chiu YL, Rosen LS et al A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors. Cancer Chemother Pharmacol 2014; 74: 583–91.
    1. Munasinghe W, Stodtmann S, Tolcher A et al Effect of veliparib (ABT‐888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo‐controlled crossover study. Cancer Chemother Pharmacol 2016; 78: 1003–11.
    1. Mizugaki H, Yamamoto N, Nokihara H et al A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT‐888) in combination with carboplatin/paclitaxel in Japanese subjects with non‐small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2015; 76: 1063–72.
    1. Murai J, Huang SY, Das BB et al Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588–99.
    1. Appleman LJ, Beumer JH, Jiang Y et al A phase I study of veliparib (ABT‐888) in combination with carboplatin and paclitaxel in advanced solid malignancies. J Clin Oncol 2012; 30(Suppl): abstract 3049.
    1. Somlo G, Frankel PH, Luu TH et al Efficacy of the combination of ABT‐888 (veliparib) and carboplatin in patients with BRCA‐associated breast cancer. J Clin Oncol 2013; 30(Suppl): abstract 1024.
    1. Pahuja S, Beumer JH, Appleman LJ et al A phase I study of veliparib (ABT‐888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple‐negative breast cancer (TNBC). J Clin Oncol 2015; 33(Suppl): abstract 1015.
    1. Rugo HS, Olopade OI, DeMichele A et al Adaptive randomization of veliparib‐carboplatin treatment in breast cancer. N Engl J Med 2016; 375: 23–34.
    1. Werner TL, Sachdev JC, Swisher EM et al Veliparib (ABT‐888) extended‐release formulations: a phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors. J Clin Oncol 2016; 34(Suppl): abstract 2579.
    1. Bell‐McGuinn KM, Brady WE, Schilder RJ et al A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 2015; 33(Suppl): abstract 5507.
    1. Isakoff SJ, Overmoyer B, Tung NM et al A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28(Suppl): abstract 1019.
    1. Isakoff SJ, Overmoyer B, Tung N et al A phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancer. Cancer Res 2011; 71(Suppl 24): abstract P3‐16‐05.
    1. Mirza MR, Monk BJ, Herrstedt J et al Niraparib maintenance therapy in platinum‐sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154–64.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir